GlassScriptPhysician profile
Gabriel Ramirez
NPI 1114252822
$4,641.55
in general payments reported to CMS, 2019-2025
16 companies · $2,123 in 2025
The $2,123 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.87 · 2022: $635 · 2023: $885 · 2024: $925 · 2025: $2,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,966 · Consulting Fee: $740 · Travel and Lodging: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,965.80 |
| Consulting Fee | $740.00 |
| Travel and Lodging | $226.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,267.77 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $875.18 | 2022-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $519.35 | 2023-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $441.93 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $434.81 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $371.55 | 2022-2025 | Caplyta |
| Gilead Sciences, INC. | $188.99 | 2021-2023 | Epclusa |
| Teva Pharmaceuticals USA, INC. | $162.94 | 2025 | Austedo Xr |
| Lundbeck LLC | $98.42 | 2022-2024 | Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $93.73 | 2021-2024 | Aristada, Lybalvi, Vivitrol |
| Indivior INC. | $59.15 | 2021-2022 | |
| Sage Therapeutics, LLC | $45.67 | 2025 | Zurzuvae |
| Lilly USA, LLC | $24.41 | 2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $21.52 | 2025 | Trintellix |
| Glaxosmithkline, LLC. | $18.67 | 2024 | Shingrix, Arexvy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $17.46 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.